IP Library Granted Patent US 11,524,096
Granted Patent B2
US 11,524,096 · App. 16/324,437 · Granted Dec 13, 2022

Wetting agent formulation

Inventors: Denzell McBurney (Castledaly Moate County, IE); Ronald John Kelly (Oranmore County, IE); Morgan Tierney (Tullamore County, IE)
Assignee: TELEFLEX LIFE SCIENCES PTE. LTD.
A61L29/085A61K39/0002A61L2/081A61L27/34A61L27/50A61L27/505A61L27/52A61L29/08A61L29/14A61L29/143A61L29/145A61M25/002B65B55/16C08L1/286A61L2/10A61L2202/18A61L2202/24A61L2400/10A61L2420/02C08J3/03C08K5/06C08K5/1345
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,524,096
App. No.
16/324,437
Granted
Dec 13, 2022
Kind
B2
Abstract

A first alternative to a composition for preventing or retarding degradation of a functional coating on a medical device includes an antioxidant selected from gallic acid or a derivative thereof. A second alternative to a composition for preventing or retarding degradation of a functional coating on a medical device includes carboxymethyl cellulose or a derivative or salt thereof. The use of the compositions for preventing or retarding degradation of a functional coating on a medical device from reactive species generated during exposure of radiation, and a wetting agent comprising the compositions, are also provided. The wetting agent prevents or retards the hydrolytic degradation of the coating during the intended shelf-life of the wetted coated product.

Claims (13)

1. A wetting liquid formulation, comprising:

a liquid comprising an aqueous or oil-based base solution, a lipid media, or a combination of both;

an antioxidant dissolved in the liquid, the antioxidant being an oxadiazole derivative of gallic acid, and further comprising a solution enhancer to increase dissolvability of the antioxidant; and

wherein wetting a medical device with the wetting liquid formulation reduces degradation of a functional coating on the medical device.

2. The wetting liquid formulation of claim 1 , wherein the oxadiazole derivative of gallic acid is present in an amount of 0.001% to 5% by weight based on a total weight of the composition.

3. The wetting liquid formulation of claim 1 , wherein the aqueous base solution is selected from a group consisting of distilled water, deionized water, reverse osmosis water, filtered water and a saline solution.

4. The wetting liquid formulation of claim 1 , wherein the aqueous base solution is present in an amount of from 50% to 99.99% by weight, based on a total weight of the composition.

5. The wetting liquid formulation of claim 1 , wherein the oxadiazole derivative of gallic acid is present as a suspension within and/or around the functional coating.

6. The wetting liquid formulation of claim 1 , further comprising a stabilizer and/or a buffer solution.

7. The wetting liquid formulation of claim 3 , wherein the solution enhancer is selected from ethylene glycol, diethylene glycol, propylene glycol, or glycerol, and is present in an amount of 0.1% to 49.8% by weight, based on the total weight of the composition.

8. The wetting liquid formulation of claim 6 , wherein the buffer solution has a pH of from 2.0 to 7.4 and wherein the buffer solution prevents the gallic acid derivatives from recrystallization.

9. The wetting liquid formulation of claim 1 , wherein the composition is free of polyvinyl alcohol.

10. The wetting liquid formulation of claim 1 , further comprising polyvinylpyrrolidone (PVP) in an amount of 0.1 to 40% by weight.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2024
From: TELEFLEX LIFE SCIENCES PTE. LTD.
To: TELEFLEX LIFE SCIENCES LLC
Reel/Frame 066616/0118 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2020
From: TELEFLEX LIFE SCIENCES UNLIMITED COMPANY
To: TELEFLEX LIFE SCIENCES PTE. LTD.
Reel/Frame 052507/0805 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2019
From: MCBURNEY, DENZELL; KELLY, RONALD JOHN; TIERNEY, MORGAN
To: TELEFLEX LIFE SCIENCES UNLIMITED COMPANY
Reel/Frame 049040/0853 →